神经病理性疼痛
药理学
化学
药代动力学
降钙素基因相关肽
止痛药
ED50公司
最大值
绝对构型
药物发现
慢性疼痛
神经元
口服
喹唑啉
作者
Jae Ho Shim,Pooreum Lim,Sangwoo Woo,Jihye Han,Hyeon Soo Kim
标识
DOI:10.1021/acs.jmedchem.6c02422
摘要
Selective Nav1.7 inhibition is a genetically validated, non-opioid strategy for chronic neuropathic pain. Herein, we report the structure-guided discovery of a quinazoline-based Nav1.7 inhibitor series. From a focused-library hit A1 (IC50 = 15.2 μM), systematic SAR across 19 analogs yielded the chiral lead (R)-(+)-A11 (IC50 = 0.98 μM; 53.9-fold selectivity over Nav1.5), with absolute configuration confirmed by MicroED (Flack x = 0.03(12)). (R)-(+)-A11 displayed favorable oral pharmacokinetics (F = 28.2%, free Cmax = 1.06 μM) and dose-dependent analgesia in mouse formalin (ED50 = 18.5 mg/kg) and rat CCI (83% MPE; ED50 = 17.1 mg/kg) models. Off-target profiling of A11 (racemate) against 44 targets showed <10% inhibition at 10 μM, and DRG CGRP target engagement by (R)-(+)-A11 (IC50 = 0.42 μM), with Nav1.7-KO neuron controls supporting Nav1.7 as the primary mechanism. These results establish (R)-(+)-A11 as a promising quinazoline lead for non-opioid neuropathic pain therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI